# US 2021/0171470 A1 · Compounds and methods for the targeted degradation of androgen receptor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171470 A1
- Document ID: US20210171470A1
- Status: Published application
- Kind: A1
- Application number: 16/888,484
- Filed: 2020-05-29
- Published: 2021-06-10
- Earliest claimed: 2016-10-11
- Assignees: Arvinas Operations, Inc.
- Applicants: Arvinas Operations, Inc.
- Inventors: Andrew P. Crew; Keith R. Hornberger; Lawrence B. Snyder; Kurt Zimmermann; Jing Wang; Michael Berlin; Craig M. Crews; Hanqing Dong
- Web page: https://patentgrep.com/patent/US20210171470A1

## CPC

- C07D 233/42: Sulfur atoms
- A61K 31/02: Halogenated hydrocarbons
- A61K 31/166: having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A61K 31/277: having a ring, e.g. verapamil
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/497: containing further heterocyclic rings
- A61K 31/501: not condensed and containing further heterocyclic rings
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61P 13/08: of the prostate
- A61P 35/00: Antineoplastic agents
- C07D 205/04: having no double bonds between ring members or between ring members and non-ring members
- C07D 209/48: with oxygen atoms in positions 1 and 3, e.g. phthalimide
- C07D 211/76: attached in position 2 or 6
- C07D 213/72: Nitrogen atoms (nitro radicals C07D213/61)
- C07D 221/20: Spiro-condensed ring systems
- C07D 231/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 237/08: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 239/24: having three or more double bonds between ring members or between ring members and non-ring members
- C07D 241/04: having no double bonds between ring members or between ring members and non-ring members
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to bifunctional compounds, which find utility to degrade and (inhibit) Androgen Receptor. In particular, the present disclosure is directed to compounds, which contain on one end a cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds Androgen Receptor, such that Androgen Receptor is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of Androgen Receptor. The present disclosure exhibits a broad range of pharmacological activities associated with compounds according to the present disclosure, consistent with the degradation/inhibition of Androgen Receptor.

## Claims

### Claim 1

A compound having the structure:
ABM-L-CLM,
wherein:
(a) CLM is a cereblon E3 ubiquitin ligase binding moiety represented by a chemical structure selected from:
wherein:
W is selected from the group consisting of CH2, CHR, C═O, SO2, NH, and N-alkyl;
each X is independently selected from the group consisting of absent, O, and S;
Y is selected from the group consisting of NH, N-alkyl, N-aryl, N-heteroaryl, N-cycloalkyl, N-heterocyclyl, O, and S;
Z is selected from the group consisting of absent, O, and S;
G and G′ are each independently selected from the group consisting of H, optionally substituted linear or branched alkyl, OH, R′OCOOR, R′OCONRR″, CH2-heterocyclyl optionally substituted with R′, and benzyl optionally substituted with R′;
Q1, Q2, Q3, and Q4 are each independently a carbon C optionally substituted with a group independently selected from H or R; or a N or N-oxide;
A is selected from the group consisting of H, alkyl, cycloalkyl, Cl and F;
n is an integer from 1 to 10;
R is selected from the group consisting of —CONR′R″, —OR′, —NR′R″, —SR′, —SO2R′, —SO2NR′R″, —CR′R″—, —CR′NR′R″—, -aryl, -heteroaryl, -optionally substituted linear or branched alkyl, -cycloalkyl, -heterocyclyl, —P(O)(OR′)R″, —P(O)R′R″, —OP(O)(OR′)R″, —OP(O)R′R″, —Cl, —F, —Br, —I, —CF3, —CN, —NR′SO2NR′R″, —NR′CONR′R″, —CONR′COR″, —NR′C(═N—CN)NR′R″, —C(═N—CN)NR′R″, —NR′C(═N—CN)R″, —NR′C(═C—NO2)NR′R″, —SO2NR′COR″, —NO2, —CO2R′, —C(C═N—OR′)R″, —CR′═CR′R″, —CCR′, —S(C═O)(C═N—R′)R″, —SF5, —R′NR′R″, (—R′O)nR″, or and —OCF3, wherein one Rn is modified to be covalently joined to the linker group (L);
R′ and R″ are each independently selected from the group consisting of a bond, H, optionally substituted linear or branched alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, or —C(═O)A, each of which is optionally substituted; and
represents a bond that may be stereospecific ((R) or (S)) or non-stereospecific;
(b) L is a chemical linker group that is covalently bound to the PTM and the CLM and has the chemical structure -(AL)q-, wherein:
q is greater than or equal to 1; and
each AL is selected from the group consisting of CRL1RL2, O, S, SO, SO2, NRL3, SO2NRL3, SONRL3, CONRL3, NRL3CONRL4, NRL3SO2NRL4, CO, CRL1═CRL2, C≡C, SiRL1RL2, P(O)RL1, P(O)ORL1, NRL3C(═NCN)NRL4, NRL3C(═NCN), NRL3C(═CNO2)NRL4, C3-11 cycloalkyl optionally substituted with 1-6 RL1 and/or RL2 groups, C5-13 spirocycloalkyl optionally substituted with 1-9 RL1 and/or RL2 groups, C3-11 heterocyclyl optionally substituted with 1-6 RL1 and/or RL2 groups, C5-13 spiroheterocycloalkyl optionally substituted with 1-8 RL1 and/or RL2 groups, aryl optionally substituted with 1-6 RL1 and/or RL2 groups, or heteroaryl optionally substituted with 1-6 RL1 and/or RL2 groups, where RL1 or RL2, each independently are optionally linked to other groups to form cycloalkyl and/or heterocyclyl moiety, optionally substituted with 1-4 RL5 groups; and
RL1, RL2, RL3, RL4 and RL5 are, each independently, H, halo, C1-8alkyl, OC1-8alkyl, SC1-8alkyl, NHC1-8alkyl, N(C1-8alkyl)2, C3-11cycloalkyl, aryl, heteroaryl, C3-11heterocyclyl, OC3-8cycloalkyl, SC3-8cycloalkyl, NHC3-8cycloalkyl, N(C3-8cycloalkyl)2, N(C3-8cycloalkyl)(C1-8alkyl), OH, NH2, SH, SO2C1-8alkyl, P(O)(OC1-8alkyl)(C1-8alkyl), P(O)(OC1-8alkyl)2, CC—C1-8alkyl, CCH, CH═CH(C1-8alkyl), C(C1-8alkyl)═CH(C1-8alkyl), C(C1-8alkyl)═C(C1-8alkyl)2, Si(OH)3, Si(C1-8alkyl)3, Si(OH)(C1-8alkyl)2, COC1-8alkyl, CO2H, halogen, CN, CF3, CHF2, CH2F, NO2, SF5, SO2NHC1-8alkyl, SO2N(C1-8alkyl)2, SONHC1-8alkyl, SON(C1-8alkyl)2, CONHC1-8alkyl, CON(C1-8alkyl)2, N(C1-8alkyl)CONH(C1-8alkyl), N(C1-8alkyl)CON(C1-8alkyl)2, NHCONH(C1-8alkyl), NHCON(C1-8alkyl)2, NHCONH2, N(C1-8alkyl)SO2NH(C1-8alkyl), N(C1-8alkyl) SO2N(C1-8alkyl)2, NH SO2NH(C1-8alkyl), NH SO2N(C1-8alkyl)2, and NH SO2NH2; and
(c) ABM is an androgen receptor (AR) binding moiety having the structure:
wherein:
W1 is aryl, heteroaryl, bicyclic, or biheterocyclic, each independently substituted by 1 or more H, halo, hydroxyl, nitro, CN, C≡CH, C2-6 alkenyl, C2-6 alkynyl, CF3, linear or branched C1-6 alkyl optionally substituted by 1 or more halo or C1-6 alkoxyl, or linear or branched C1-6 alkoxyl optionally substituted by 1 or more halo;
Y3 are each independently a bond, O, NRY2, CRY1RY2, C═O, C═S, SO, SO2, heteroaryl, or aryl;
Q is a 5- or 6-membered ring with 0-4 heteroatoms, optionally substituted with 0-6 RQ;
each RQ is independently: H; halogen; C1-6 alkoxy; linear or branched C1-6 alkyl optionally substituted by 1 or more halo or C1-6 alkoxyl; or 2 RQ groups taken together with the atom they are attached to, form a 3-8 membered ring system containing 0-2 heteroatoms;
RY1, RY2 are each independently H, halogen, C1-6 alkoxy, cyclic, heterocyclic, linear or branched C1-6 alkyl optionally substituted by 1 or more halo or C1-6 alkoxyl;
W2 is C1-6 alkyl, C1-6 heteroalkyl, O, aryl, heteroaryl, alicyclic, heterocyclic, biheterocyclic, biaryl, or biheteroaryl, each optionally substituted by 1-10 RW2;
each RW2 is independently: H; halo; C1-6 alkyl optionally substituted by 1 or more F; C3-6 cycloalkyl; C4-6 cycloheteroalkyl; optionally substituted C1-6 alkyl; optionally substituted C1-6 alicyclic; optionally substituted heterocyclic; optionally substituted aryl; optionally substituted heteroaryl; optionally substituted bicyclic heteroaryl; optionally substituted bicyclic aryl; OH; NH2; NRY1RY2; CN; or OC1-3alkyl optionally substituted by 1 or more —F; and
is the point of attachment of the ABM to the chemical linker group (L).

### Claim 2 (depends on 1)

The bifunctional compound according to claim 1, wherein the ABM has the chemical structure:
wherein:
Y4 and Y5 are each individually selected from: a bond, O, NRY2, CRY1RY2, C═O, C═S, SO, SO2, heteroaryl, or aryl; and
is the point of attachment of the ABM to the chemical linker group (L).

### Claim 3 (depends on 1)

The compound of claim 1, wherein W1 is selected from the group consisting of:

### Claim 4 (depends on 2)

The compound of claim 2, wherein W2 is selected from the group consisting of:

### Claim 5 (depends on 1)

The bifunctional compound according to claim 1, wherein W2 is selected from the group consisting of:

### Claim 6 (depends on 1)

The bifunctional compound according to claim 1, wherein the ABM is selected from the group consisting of:
wherein:
RQ2 is a H, halogen, CH3 or CF3; and
RQ3 is a H, halo, hydroxyl, nitro, CN, C≡CH, C2-6 alkenyl, C2-6 alkynyl, or CF3, a linear or branched C1-6 alkyl optionally substituted by 1 or more halo or C1-6 alkoxyl, or a linear or branched C1-6 alkoxyl optionally substituted by 1 or more halo;
Y3, Y4, Y5 are each independently a bond, O, NRY2, CRY1RY2, C═O, heteroaryl, or aryl;
RY1, RY2 are each independently H, or linear or branched C1-6 alkyl optionally substituted by 1 or more halo, C1-6 alkoxyl, cyclic, or heterocyclic; and
X is N or C.

### Claim 7 (depends on 1)

The bifunctional compound according to claim 1, wherein the ABM is selected from the group consisting of:

### Claim 8 (depends on 1)

The compound of claim 1, wherein the CLM has a chemical structure represented by:

### Claim 9 (depends on 1)

The compound of claim 1, wherein the CLM has a chemical structure represented by:
wherein:
W is independently selected from the group CH2, C═O, NH, and N-alkyl;
A independently selected from a H, methyl, alkyl;
represents a bond that may be stereospecific ((R) or (S)) or non-stereospecific; and
n is an integer from 1 to 4, wherein one Rn is modified to be covalently joined to the linker group (L).

### Claim 10 (depends on 1)

The compound of claim 1, wherein the L has 1-25 optionally substituted ethylene glycol units wherein each O is optionally replaced with an optionally substituted N, S, P, or Si atom.

### Claim 11 (depends on 1)

The bifunctional compound of claim 1, wherein L has 1-10 optionally substituted ethylene glycol units wherein each O is optionally replaced with an optionally substituted N atom.

### Claim 12 (depends on 1)

The bifunctional compound according to claim 1, wherein linker (L) comprises a group represented by a general structure selected from the group consisting of:
—N(R)—(CH2)m—O(CH2)n—O(CH2)o—O(CH2)p—O(CH2)q—O(CH2)r—OCH2-, —O—(CH2)m—O(CH2)n—O(CH2)o—(CH2)p—O(CH2)q—O(CH2)r—OCH2-, —O—(CH2)m—O(CH2)n—O(CH2)o—O(CH2)p—O(CH2)q—O(CH2)r—O—; —N(R)—(CH2)m—O(CH2)n—O(CH2)o—O(CH2)p—O(CH2)q—O(CH2)r—O—; —(CH2)m—O(CH2)n—O(CH2)o—O(CH2)p—O(CH2)q—O(CH2)r—O—; —(CH2)m—O(CH2)n—O(CH2)o—O(CH2)p—O(CH2)q—O(CH2)r—OCH2-;
wherein m, n, o, p, q, and r are each independently 0, 1, 2, 3, 4, 5, 6, with the proviso that when the number is zero, there is no N—O or O—O bond, R is selected from the group H, methyl or ethyl, and X is selected from the group H and F;
wherein n and m are each independently 0, 1, 2, 3, 4, 5, 6, and X is H, or F.

### Claim 13 (depends on 1)

The bifunctional compound according to claim 1, wherein linker (L) is selected from the group consisting of:

### Claim 14 (depends on 1)

The bifunctional compound according to claim 1, wherein the linker (L) comprises a group represented by a general structure:
wherein m can be 2, 3, 4, 5.

### Claim 15 (depends on 1)

The bifunctional compound according to claim 1, wherein the compound is a member selected from the group consisting of Examples 1-399, 402, 409-413, and 415-625 from Tables 2-7, a salt, a polymorph, isostere, and a prodrug thereof.

### Claim 16 (depends on 1)

A composition comprising an effective amount of a bifunctional compound of claim 1, and a pharmaceutically acceptable carrier.

### Claim 17 (depends on 16)

The composition of claim 16, wherein the composition further comprises at least one bioactive agent.

### Claim 18 (depends on 17)

The composition of claim 17, wherein the bioactive agent is an anti-cancer agent.

### Claim 19

A compound having the structure:
ABM-L-CLM,
wherein:
(a) CLM is a cereblon E3 ubiquitin ligase binding moiety represented by a chemical structure selected from:
wherein:
W is selected from the group consisting of CH2, CHR, C═O, SO2, NH, and N-alkyl;
each X is independently selected from the group consisting of absent, O, and S;
Y is selected from the group consisting of NH, N-alkyl, N-aryl, N-heteroaryl, N-cycloalkyl, N-heterocyclyl, O, and S;
Z is selected from the group consisting of absent, O, and S;
G and G′ are each independently selected from the group consisting of H, optionally substituted linear or branched alkyl, OH, R′OCOOR, R′OCONRR″, CH2-heterocyclyl optionally substituted with R′, and benzyl optionally substituted with R′;
Q1, Q2, Q3, and Q4 are each independently a carbon C optionally substituted with a group independently selected from H or R; or a N or N-oxide;
A is selected from the group consisting of H, alkyl, cycloalkyl, Cl and F;
n is an integer from 1 to 10;
R is selected from the group consisting of —CONR′R″, —OR′, —NR′R″, —SR′, —SO2R′, —SO2NR′R″, —CR′R″—, —CR′NR′R″—, -aryl, -heteroaryl, -optionally substituted linear or branched alkyl, -cycloalkyl, -heterocyclyl, —P(O)(OR′)R″, —P(O)R′R″, —OP(O)(OR′)R″, —OP(O)R′R″, —Cl, —F, —Br, —I, —CF3, —CN, —NR′SO2NR′R″, —NR′CONR′R″, —CONR′COR″, —NR′C(═N—CN)NR′R″, —C(═N—CN)NR′R″, —NR′C(═N—CN)R″, —NR′C(═C—NO2)NR′R″, —SO2NR′COR″, —NO2, —CO2R′, —C(C═N—OR′)R″, —CR′═CR′R″, —CCR′, —S(C═O)(C═N—R′)R″, —SF5, —R′NR′R″, (—R′O)nR″, or and —OCF3, wherein one Rn is modified to be covalently joined to the linker group (L);
R′ and R″ are each independently selected from the group consisting of a bond, H, optionally substituted linear or branched alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, or —C(═O)A, each of which is optionally substituted; and
represents a bond that may be stereospecific ((R) or (S)) or non-stereospecific;
(b) L is a chemical linker group that is covalently bound to the PTM and the CLM and has the chemical structure -(AL)q-, wherein:
q is greater than or equal to 1; and
each AL is selected from the group consisting of CRL1RL2, O, S, SO, SO2, NRL3, SO2NRL3, SONRL3, CONRL3, NRL3CONRL4, NRL3SO2NRL4, CO, CRL1═CRL2, C≡C, SiRL1RL2, P(O)RL1, P(O)ORL1, NRL3C(═NCN)NRL4, NRL3C(═NCN), NRL3C(═CNO2)NRL4, C3-11 cycloalkyl optionally substituted with 1-6 RL1 and/or RL2 groups, C5-13 spirocycloalkyl optionally substituted with 1-9 RL1 and/or RL2 groups, C3-11 heterocyclyl optionally substituted with 1-6 RL1 and/or RL2 groups, C5-13 spiroheterocycloalkyl optionally substituted with 1-8 RL1 and/or RL2 groups, aryl optionally substituted with 1-6 RL1 and/or RL2 groups, or heteroaryl optionally substituted with 1-6 RL1 and/or RL2 groups, where RL1 or RL2, each independently are optionally linked to other groups to form cycloalkyl and/or heterocyclyl moiety, optionally substituted with 1-4 RL5 groups; and
RL1, RL2, RL3, RL4 and RL5 are, each independently, H, halo, C1-8alkyl, OC1-8alkyl, SC1-8alkyl, NHC1-8alkyl, N(C1-8alkyl)2, C3-11cycloalkyl, aryl, heteroaryl, C3-11heterocyclyl, OC3-8cycloalkyl, SC3-8cycloalkyl, NHC3-8cycloalkyl, N(C3-8cycloalkyl)2, N(C3-8cycloalkyl)(C1-8alkyl), OH, NH2, SH, SO2C1-8alkyl, P(O)(OC1-8alkyl)(C1-8alkyl), P(O)(OC1-8alkyl)2, CC—C1-8alkyl, CCH, CH═CH(C1-8alkyl), C(C1-8alkyl)═CH(C1-8alkyl), C(C1-8alkyl)═C(C1-8alkyl)2, Si(OH)3, Si(C1-8alkyl)3, Si(OH)(C1-8alkyl)2, COC1-8alkyl, CO2H, halogen, CN, CF3, CHF2, CH2F, NO2, SF5, SO2NHC1-8alkyl, SO2N(C1-8alkyl)2, SONHC1-8alkyl, SON(C1-8alkyl)2, CONHC1-8alkyl, CON(C1-8alkyl)2, N(C1-8alkyl)CONH(C1-8alkyl), N(C1-8alkyl)CON(C1-8alkyl)2, NHCONH(C1-8alkyl), NHCON(C1-8alkyl)2, NHCONH2, N(C1-8alkyl)SO2NH(C1-8alkyl), N(C1-8alkyl) SO2N(C1-8alkyl)2, NH SO2NH(C1-8alkyl), NH SO2N(C1-8alkyl)2, and NH SO2NH2; and
(c) ABM is an androgen receptor (AR) binding moiety having the structure:
wherein:
W1 is aryl, heteroaryl, bicyclic, or biheterocyclic, each independently substituted by 1 or more H, halo, hydroxyl, nitro, CN, C≡CH, C2-6 alkenyl, C2-6 alkynyl, CF3, linear or branched C1-6 alkyl optionally substituted by 1 or more halo or C1-6 alkoxyl, or linear or branched C1-6 alkoxyl optionally substituted by 1 or more halo;
Y3 are each independently a bond, 0, NRY2, CRY1RY2, C═O, C═S, SO, SO2, heteroaryl, or aryl;
Q is a 4-6 membered ring with 0-4 heteroatoms, optionally substituted with 0-6 RQ;
each RQ is independently: H; halogen; C1-6 alkoxy; linear or branched C1-6 alkyl optionally substituted by 1 or more halo or C1-6 alkoxyl; or 2 RQ groups taken together with the atom they are attached to, form a 3-8 membered ring system containing 0-2 heteroatoms;
RY1, RY2 are each independently H, halogen, C1-6 alkoxy, cyclic, heterocyclic, linear or branched C1-6 alkyl optionally substituted by 1 or more halo or C1-6 alkoxyl;
W2 is heteroaryl, heterocyclic, biheterocyclic, or biheteroaryl, each optionally substituted by 1-10 RW2;
each RW2 is independently: H; halo; C1-6 alkyl optionally substituted by 1 or more F; C3-6 cycloalkyl; C4-6 cycloheteroalkyl; optionally substituted C1-6 alkyl; optionally substituted C1-6 alicyclic; optionally substituted heterocyclic; optionally substituted aryl; optionally substituted heteroaryl; optionally substituted bicyclic heteroaryl; optionally substituted bicyclic aryl; OH; NH2; NRY1RY2; CN; or OC1-3alkyl optionally substituted by 1 or more —F; and
is the point of attachment of the ABM to the chemical linker group (L).

### Claim 20

A compound selected from the group consisting of:
